INTRODUCING ACTIM® PARTUS 1NGENI

QUANTITATIVE CONFIDENCE FOR PRETERM LABOUR

INTRODUCING ACTIM® PARTUS 1NGENI

QUANTITATIVE CONFIDENCE FOR PRETERM LABOUR

NOW THERE’S ANOTHER CHOICE FOR QUANTITATIVE PREDICTION OF PRETERM DELIVERY

The Actim® Partus 1ngeni test not only detects or rules out the risk of preterm or imminent delivery, but also provides precise data about the severity of the risk.

The test detects and measures the level of phosphorylated insulin-like growth factor-binding protein-1 in cervical secretions. The higher the concentration, the higher the risk.

NOW THERE’S ANOTHER CHOICE FOR QUANTITATIVE PREDICTION OF PRETERM DELIVERY

The Actim® Partus 1ngeni test not only detects or rules out the risk of preterm or imminent delivery, but also provides precise data about the severity of the risk.

The test detects and measures the level of phosphorylated insulin-like growth factor-binding protein-1 in cervical secretions. The higher the concentration, the higher the risk.

THE ACTIM® PARTUS 1NGENI TEST IS PERFORMED USING THE ACTIM® 1NGENI INSTRUMENT AND PROVIDES

RELIABLE AND FAST RESULTS

Test results are available in just 5 minutes at the bedside and are not affected by intercourse, semen, urine, vaginal medications, lubricants, bathing products or infections.

Clinical evidence from multiple studies shows that Actim® Partus has a very high (98%) negative predictive value (NPV) as a predictor of delivery before week 32–37 and within 7 days1-9.

EARLY PREDICTION OF PRETERM OR IMMINENT DELIVERY

The Actim® Partus 1ngeni test is conducted using cervical secretions collected from women with intact fetal membranes and can be performed from gestational week 22 onwards. Accurate detection of an elevated risk is crucial for choosing the right treatment early.

CLEAR QUANTIFICATION AND INTERPRETATION OF TEST RESULTS

The phIGFBP-1 concentration is reported as a numerical value with the description of the estimated risk for preterm or imminent labour:

  • < 10 μg/l, low risk of preterm delivery
  • ≥ 10 μg/l, elevated risk of preterm delivery

FAST AND EASY TESTING WITH TRACEABLE DOCUMENTATION

Automated testing and digital data storage save time and ensure assay consistency.

DOWNLOAD THE BROCHURES BELOW OR CONTACT US FOR MORE INFORMATION USING THE FORM ABOVE.  ALSO ASK US ABOUT OUR ACTIM® PROM TEST.

Desktop divider
Mobile divider

DOWNLOAD BROCHURE

USING ACTIM® PROM &
PARTUS TESTS TOGETHER

LEARN MORE ABOUT THE ACTIM® PARTUS TEST

References
1. Tripathi, R. et al.., 2016. Comparison of rapid bedside tests for phosphorylated insulin-like growth factor-binding protein 1 and fetal fibronectin to predict preterm birth. International Journal of Gynecology & Obstetrics, 135(1), pp.47-50.
2. Azlin, M. et al.., 2010. Role of phIGFBP-1 and ultrasound cervical length in predicting pre-term labour. Journal of Obstetrics and Gynaecology, 30(5), pp.456-459.
3. Brik, M. et al.., 2010. Phosphorylated insulin-like growth factor binding protein-1 and cervical measurement in women with threatening preterm birth. Acta Obstetricia et Gynecologica Scandinavica, 89(2), pp.268-274.
4. Tanir, H. et al.., 2009. Cervical phosphorylated insulin-like growth factor binding proteın-1 for the prediction of preterm delivery in symptomatic cases with intact membranes. Journal of Obstetrics and Gynaecology Research, 35(1), pp.66-72.
5. Eroglu, D. et al.., 2007. Prediction of Preterm Delivery among Women with Threatened Preterm Labor. Gynecologic and Obstetric Investigation, 64(2), pp.109-116.
6. Ting, H. et al.., 2007. Comparison of bedside test kits for prediction of preterm delivery: Phosphorylated insulin-like growth factor binding protein-1 (pIGFBP-1) test and fetal fibronectin test. Annals of the Academy of Medicine, Singapore, 36(6), pp.399-402.
7. Lembet, A. et al.., 2002. New rapid bed-side test to predict preterm delivery: phosphorylated insulin-like growth factor binding protein-1 in cervical secretions. Acta Obstetricia et Gynecologica Scandinavica, 81(8), pp.706-712.
8. Kekki, M. et al.., 2001. Insulin-like growth factor-binding protein-1 in cervical secretion as a predictor of preterm delivery.Acta Obstetricia et Gynecologica Scandinavica, 80(6), pp.546-551.
9. Akercan, F. et al.., 2004. Value of cervical phosphorylated insulin-like growth factor binding protein-1 in the prediction of preterm labor. The Journal of Reproductive Medicine, 49(5), pp.368-372

©2021 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy: US Citizens | Non US Citizens. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. COL-06478 07/21

References
1. Tripathi, R. et al.., 2016. Comparison of rapid bedside tests for phosphorylated insulin-like growth factor-binding protein 1 and fetal fibronectin to predict preterm birth. International Journal of Gynecology & Obstetrics, 135(1), pp.47-50.
2. Azlin, M. et al.., 2010. Role of phIGFBP-1 and ultrasound cervical length in predicting pre-term labour. Journal of Obstetrics and Gynaecology, 30(5), pp.456-459.
3. Brik, M. et al.., 2010. Phosphorylated insulin-like growth factor binding protein-1 and cervical measurement in women with threatening preterm birth. Acta Obstetricia et Gynecologica Scandinavica, 89(2), pp.268-274.
4. Tanir, H. et al.., 2009. Cervical phosphorylated insulin-like growth factor binding proteın-1 for the prediction of preterm delivery in symptomatic cases with intact membranes. Journal of Obstetrics and Gynaecology Research, 35(1), pp.66-72.
5. Eroglu, D. et al.., 2007. Prediction of Preterm Delivery among Women with Threatened Preterm Labor. Gynecologic and Obstetric Investigation, 64(2), pp.109-116.
6. Ting, H. et al.., 2007. Comparison of bedside test kits for prediction of preterm delivery: Phosphorylated insulin-like growth factor binding protein-1 (pIGFBP-1) test and fetal fibronectin test. Annals of the Academy of Medicine, Singapore, 36(6), pp.399-402.
7. Lembet, A. et al.., 2002. New rapid bed-side test to predict preterm delivery: phosphorylated insulin-like growth factor binding protein-1 in cervical secretions. Acta Obstetricia et Gynecologica Scandinavica, 81(8), pp.706-712.
8. Kekki, M. et al.., 2001. Insulin-like growth factor-binding protein-1 in cervical secretion as a predictor of preterm delivery.Acta Obstetricia et Gynecologica Scandinavica, 80(6), pp.546-551.
9. Akercan, F. et al.., 2004. Value of cervical phosphorylated insulin-like growth factor binding protein-1 in the prediction of preterm labor. The Journal of Reproductive Medicine, 49(5), pp.368-372

©2021 Abbott. All rights reserved. Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. Your use of this website and the information contained herein is subject to our Website Terms and Conditions and Privacy Policy: US Citizens | Non US Citizens. Photos displayed are for illustrative purposes only. Any person depicted in such photographs is a model. COL-06478 07/21